ABBV-151 is under clinical development by AbbVie and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ABBV-151’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ABBV-151 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ABBV-151 overview

ABBV-151 is under development for the treatment of colorectal cancer, pancreatic adenocarcinoma, urothelial cancer, hepatocellular carcinoma (HCC), advanced or metastatic solid tumors, head and neck squamous cell carcinoma (HNSCC), oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer and laryngeal cancer. The therapeutic candidate is developed based on the SIMPLE Antibody platform technology. It is administered as a liquid for intravenous infusion. It acts by targeting cell surface membrane protein GARP.

It was also under development for the treatment of graft versus host disease,  triple-negative breast cancer (TNBC).

AbbVie overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

Quick View ABBV-151 LOA Data

Report Segments
  • Innovator
Drug Name
  • ABBV-151
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
  • Oncology
Key Developers
  • Sponsor Company: AbbVie
  • Originator: Ludwig Institute For Cancer Research and Catholic University of Louvain
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.